Leerink Partners Reaffirms Their Buy Rating on Natera (NTRA)We are reiterating our confidence in NTRA (a top pick for 2Q25 earnings) in light of the continued weakness (down 7.1% in the last week and 19.1% in the last month, vs. XBI up 0.5% and the last week and up 7.2%, 5.7%, respectively, in the last month). We expect a strong beat on revenue and, more importantly, Signatera volumes to beat cons. (11.3k tests) and our 11.8k est. handily. Investor inbounds have increased with the recent sell-off and point to questions of whether NTRA will raise its OpEx guidance, and as to the emerging competitive entrants in the market. We agree that an OpEx guidance raise is likely given the priority that NTRA has to maintain its lead in the $20B (LP est) MRD market, where it's on track to deliver more than $860M+ in our model this year. Our prior conversations with the mgmt.